What question did this study set out to answer?

To compare the efficacy and safety of different fixed-ratio combination products in treating type 2 diabetes.

March 30, 2026Journal of Diabetes Investigation0 citationsOpen Access

Comparative efficacy and safety of three fixed‐ratio combination products in type 2 diabetes: A network meta‐analysis

Key Points

To compare the efficacy and safety of different fixed-ratio combination products in treating type 2 diabetes.
Conducted a network meta-analysis among three fixed-ratio combination products.
Assessed glycemic control by measuring HbA1c and FPG levels.
Evaluated safety profiles based on incidence rates of treatment-emergent adverse events (TEAEs).
IDegLira demonstrated the highest effectiveness for glycemic control.
IDegAsp showed a better safety profile with lower incidence of TEAEs.

Abstract

Among the three fixed-ratio combination products, IDegLira appears most effective for glycemic control (in terms of HbA1c and FPG reduction), whereas IDegAsp demonstrates the best safety profile regarding incidence of TEAEs.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Wang et al. (Sat,) studied this question.

synapsesocial.com/papers/69c9c5a4f8fdd13afe0bd862 https://doi.org/https://doi.org/10.1111/jdi.70293

AI से पूछें

Bookmark

View Full Paper